Literature DB >> 15219501

Usefulness of electrocardiographic-gated stress technetium-99m sestamibi single-photon emission computed tomography to differentiate ischemic from nonischemic cardiomyopathy.

Peter G Danias1, Georgios I Papaioannou, Alan W Ahlberg, David M O'Sullivan, April Mann, William E Boden, Gary V Heller.   

Abstract

The noninvasive differentiation between ischemic and nonischemic cardiomyopathy is frequently difficult. We examined the clinical value of stress electrocardiographic gated (ECG-gated) single-photon emission computed tomography (SPECT) to identify ischemic cardiomyopathy and detect coronary artery disease (CAD) in 164 patients without known CAD, ejection fraction < or =40% by ECG-gated SPECT, and subsequent coronary angiography. Summed stress, rest, and difference scores were measured from the SPECT studies, and regional wall motion variance was calculated from the ECG-gated images. Sensitivity and 95% confidence intervals for the diagnosis of ischemic cardiomyopathy and for detection of any CAD (>50% diameter stenosis) were estimated using previously defined cutoffs for summed stress score and regional wall motion variance. For the diagnosis of ischemic cardiomyopathy, sensitivity of stress SPECT (summed stress score >8) was 87% (95% confidence interval [CI] 78 to 95), with a specificity of 63% (95% CI 60 to 82). The addition of wall motion information (summed stress score >8 or regional wall motion variance >0.114) increased sensitivity to 88% (95% CI 80 to 96) and decreased specificity to 45% (95% CI 35 to 55). If reversibility was also taken into account (summed stress score >8, regional wall motion variance >0.114, or summed difference score >0), sensitivity further increased to 94% (95% CI 88 to 100) and specificity decreased to 32% (95% CI 23 to 41). For detection of any CAD, the combined approach using stress perfusion, reversibility, and region of wall motion had a sensitivity of 94% (95% CI 89 to 99) and a specificity of 45% (95% CI 35 to 57). Therefore, ECG-gated SPECT is very sensitive for detection of ischemic cardiomyopathy and CAD among patients with moderate to severe systolic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15219501     DOI: 10.1016/j.amjcard.2004.03.022

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  18 in total

1.  Comparison of gated single-photon emission computed tomography with magnetic resonance imaging for evaluation of left ventricular volumes and ejection fraction in patients with idiopathic dilated cardiomyopathy.

Authors:  Petri Sipola; Keijo Peuhkurinen; Esko Vanninen
Journal:  Int J Cardiovasc Imaging       Date:  2010-09-28       Impact factor: 2.357

Review 2.  The role of radionuclide imaging in heart failure.

Authors:  Vinay Gulati; Gilbert Ching; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

3.  American Society of Nuclear Cardiology review of the ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI).

Authors:  R Parker Ward; Mouaz H Al-Mallah; Gabriel B Grossman; Christopher L Hansen; Robert C Hendel; Todd C Kerwin; Benjamin D McCallister; Rupa Mehta; Donna M Polk; Peter L Tilkemeier; Aseem Vashist; Kim Allan Williams; David G Wolinsky; Edward P Ficaro
Journal:  J Nucl Cardiol       Date:  2007 Nov-Dec       Impact factor: 5.952

Review 4.  Radionuclide noninvasive evaluation of heart failure beyond left ventricular function assessment.

Authors:  Albert Flotats; Ignasi Carrió
Journal:  J Nucl Cardiol       Date:  2009-02-27       Impact factor: 5.952

5.  Evaluation of left ventricular volumes and ejection fraction by gated SPECT and cardiac MRI in patients with dilated cardiomyopathy.

Authors:  Feng Wang; Jian Zhang; Wei Fang; Shi-Hua Zhao; Min-Jie Lu; Zuo-Xiang He
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-18       Impact factor: 9.236

Review 6.  SPECT and PET in ischemic heart failure.

Authors:  George Angelidis; Gregory Giamouzis; Georgios Karagiannis; Javed Butler; Ioannis Tsougos; Varvara Valotassiou; George Giannakoulas; Nikolaos Dimakopoulos; Andrew Xanthopoulos; John Skoularigis; Filippos Triposkiadis; Panagiotis Georgoulias
Journal:  Heart Fail Rev       Date:  2017-03       Impact factor: 4.214

7.  Direct quantification of left ventricular motion and thickening changes using rest-stress myocardial perfusion SPECT.

Authors:  Shahryar Karimi-Ashtiani; Reza Arsanjani; Mathews Fish; Paul Kavanagh; Guido Germano; Daniel Berman; Piotr Slomka
Journal:  J Nucl Med       Date:  2012-08-07       Impact factor: 10.057

8.  Prospective diagnostic performance of semiconductor SPECT myocardial perfusion imaging: wall thickening analysis reduces the need for an additional prone acquisition.

Authors:  Loïc Djaileb; Benjamin Dubois; Nicolas de Leiris; Julien Leenhardt; Marjorie Canu; Olivier Phan Sy; Adrien Carabelli; Bastien Boussat; Laurent Dumas; Alexis Broisat; Gérald Vanzetto; Daniel Fagret; Catherine Ghezzi; Gilles Barone-Rochette; Laurent M Riou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-18       Impact factor: 9.236

9.  Myocardial perfusion, function, and dyssynchrony in patients with heart failure: baseline results from the single-photon emission computed tomography imaging ancillary study of the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Trial.

Authors:  Allen E Atchley; Dalane W Kitzman; David J Whellan; Ami E Iskandrian; Stephen J Ellis; Robert A Pagnanelli; Andrew Kao; Khaled Abdul-Nour; Christopher M O'Connor; Greg Ewald; William E Kraus; Salvador Borges-Neto
Journal:  Am Heart J       Date:  2009-10       Impact factor: 4.749

10.  Regional wall-motion abnormalities on post-stress electrocardiographic-gated technetium-99m sestamibi single-photon emission computed tomography imaging predict cardiac events.

Authors:  Athanasios Kapetanopoulos; Alan W Ahlberg; Cynthia C Taub; Deborah M Katten; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2007 Nov-Dec       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.